KR20240058976A - 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 - Google Patents

지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Download PDF

Info

Publication number
KR20240058976A
KR20240058976A KR1020247013455A KR20247013455A KR20240058976A KR 20240058976 A KR20240058976 A KR 20240058976A KR 1020247013455 A KR1020247013455 A KR 1020247013455A KR 20247013455 A KR20247013455 A KR 20247013455A KR 20240058976 A KR20240058976 A KR 20240058976A
Authority
KR
South Korea
Prior art keywords
eye
implant
biodegradable
patients
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247013455A
Other languages
English (en)
Korean (ko)
Inventor
제인-구오 시아
라훌 바가트
웬디 엠. 블랜다
티에리 니바지올리
린 펭
데이비드 초우
데이비드 에이. 웨버
Original Assignee
알레간 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240058976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알레간 인코포레이티드 filed Critical 알레간 인코포레이티드
Publication of KR20240058976A publication Critical patent/KR20240058976A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020247013455A 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법 Ceased KR20240058976A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
KR1020227018854A KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018854A Division KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Publications (1)

Publication Number Publication Date
KR20240058976A true KR20240058976A (ko) 2024-05-07

Family

ID=52001114

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247013455A Ceased KR20240058976A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020227018854A Ceased KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227018854A Ceased KR20220082934A (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법
KR1020167015466A Active KR102475746B1 (ko) 2013-11-15 2014-11-14 지연된 약물전달 임플란트에 의한 눈 질환의 치료방법

Country Status (24)

Country Link
US (2) US20150140062A1 (https=)
EP (2) EP3714875A1 (https=)
JP (2) JP6675307B2 (https=)
KR (3) KR20240058976A (https=)
CN (1) CN105764517A (https=)
AU (4) AU2014348369B2 (https=)
CA (1) CA2929689A1 (https=)
CL (1) CL2016001167A1 (https=)
CY (1) CY1123344T1 (https=)
DK (1) DK3068403T3 (https=)
ES (1) ES2819215T5 (https=)
HU (1) HUE050913T2 (https=)
IL (2) IL245548A0 (https=)
MX (2) MX2016006334A (https=)
MY (1) MY176039A (https=)
NZ (1) NZ719953A (https=)
PH (1) PH12016500869A1 (https=)
PL (1) PL3068403T3 (https=)
PT (1) PT3068403T (https=)
RU (1) RU2690841C1 (https=)
SG (1) SG10201809363SA (https=)
SI (1) SI3068403T1 (https=)
UA (1) UA122117C2 (https=)
WO (1) WO2015073895A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3174217A1 (en) * 2020-07-16 2022-01-20 Ocular Therapeutix, Inc. Ocular insert containing a glucocorticoid
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法

Also Published As

Publication number Publication date
AU2024205640A1 (en) 2024-08-29
US20250319031A1 (en) 2025-10-16
AU2020204362A1 (en) 2020-07-23
NZ719953A (en) 2022-01-28
RU2016119132A (ru) 2017-12-20
ES2819215T3 (es) 2021-04-15
AU2014348369B2 (en) 2020-04-02
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
RU2690841C1 (ru) 2019-06-06
SI3068403T1 (sl) 2020-11-30
MX2016006334A (es) 2016-09-06
ES2819215T5 (en) 2026-04-01
MX2022002306A (es) 2022-03-25
EP3714875A1 (en) 2020-09-30
EP3068403B1 (en) 2020-06-17
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08
HUE050913T2 (hu) 2021-01-28
SG10201809363SA (en) 2018-11-29
JP6675307B2 (ja) 2020-04-01
UA122117C2 (uk) 2020-09-25
KR20160085847A (ko) 2016-07-18
PH12016500869B1 (en) 2016-07-04
US20150140062A1 (en) 2015-05-21
DK3068403T3 (da) 2020-09-07
WO2015073895A1 (en) 2015-05-21
KR20220082934A (ko) 2022-06-17
CL2016001167A1 (es) 2017-01-06
CA2929689A1 (en) 2015-05-21
KR102475746B1 (ko) 2022-12-08
JP2020055862A (ja) 2020-04-09
CN105764517A (zh) 2016-07-13
PH12016500869A1 (en) 2016-07-04
IL290837A (en) 2022-04-01
AU2024205640B2 (en) 2025-10-23
EP3068403A1 (en) 2016-09-21
PL3068403T3 (pl) 2021-01-11
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
JP7022735B2 (ja) 2022-02-18
IL245548A0 (en) 2016-06-30
AU2014348369A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
AU2024205640B2 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
US20230172948A1 (en) Ocular implant made by a double extrusion proces
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
Lee et al. Novel drug delivery systems for retinal diseases: a review
RU2015144119A (ru) Ускоренное заживление повреждений глаз с помощью ангиотензиновых пептидов
de Oliveira Dias et al. New drugs and new posterior delivery methods in CME
Suresh et al. Ocular implants as drug delivery device in opthalmic therapeutics: An overview
Kuppermann et al. Drug delivery to the posterior segment of the eye
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Lee et al. Posterior subtenon triamcinolone acetonide in gas-filled eyes as an adjunctive treatment for complicated proliferative diabetic retinopathy
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
Au The New Era of Glaucoma Micro-stent Surgery
Barman et al. Sustained drug delivery in the posterior segments of the eye
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240423

Application number text: 1020227018854

Filing date: 20220603

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240523

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241209

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250304

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D